AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10700536 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (Group I, n=15)
Number of subjects: 22
Study 10700536 — intervention group
Group type: COMPARATOR
Intervention: Hypocaloric parenteral nutrition (Group II, n=7)
Number of subjects: 22
Study 10700536 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (Group I)
Number of subjects: 22
Study 10700536 — intervention group
Group type: COMPARATOR
Intervention: Hypocaloric parenteral nutrition (Group II)
Number of subjects: 22
Study 10700536 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 22
Study 8851401 — intervention group
Group type: EXPERIMENTAL
Intervention: CTAP
Number of subjects: 26
Study 8851401 — intervention group
Group type: COMPARATOR
Intervention: MR imaging
Number of subjects: 26
Study 1391107 — intervention group
Group type: COMPARATOR
Intervention: Conventional fluid therapy (Control Group I)
Number of subjects: 35
Study 1391107 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional support based on glucose and aminoacid (Group II)
Number of subjects: 35
Study 1391107 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional therapy based on glycerol and aminoacid (Group III)
Number of subjects: 35
Study 6437257 — intervention group
Group type: EXPERIMENTAL
Intervention: Cessation and maintenance manuals (C + M)
Number of subjects: 1237
Study 6437257 — intervention group
Group type: COMPARATOR
Intervention: Leaflets (L)
Number of subjects: 1237
Study 6437257 — intervention group
Group type: EXPERIMENTAL
Intervention: Leaflets plus maintenance manual (L + M)
Number of subjects: 1237
Study 6437257 — intervention group
Group type: EXPERIMENTAL
Intervention: Cessation manual (C)
Number of subjects: 1237
Study 31567637 — intervention group
Group type: EXPERIMENTAL
Intervention: Split-dose polyethylene glycol with electrolyte solution
Number of subjects: 45
Study 31567637 — intervention group
Group type: COMPARATOR
Intervention: Full single-dose polyethylene glycol with electrolyte solution
Number of subjects: 45
Study 29730649 — intervention group
Group type: EXPERIMENTAL
Intervention: DXplain intervention group (43 residents)
Number of subjects: 87
Study 29730649 — intervention group
Group type: COMPARATOR
Intervention: Control group (44 residents)
Number of subjects: 87
Study 28294745 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 126
Study 28294745 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine
Number of subjects: 126
Study 24595632 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-complex carbohydrate (HCC)/lower-fat (LF) CHOICE diet (60% carbohydrate, 25% fat, 15% protein)
Number of subjects: 16
Study 24595632 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-complex carbohydrate (HCC)/lower-fat (LF) CHOICE diet
Number of subjects: 16
Study 24595632 — intervention group
Group type: COMPARATOR
Intervention: Conventional lower-carbohydrate/HF diet (40% carbohydrate, 45% fat, 15% protein)
Number of subjects: 16
Study 22866767 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive treatment (≥3 concomitantly used antihypertensive medications)
Number of subjects: 22576
Study 22866767 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (≤2 concomitantly used antihypertensive medications)
Number of subjects: 22576
Study 20560814 — intervention group
Group type: EXPERIMENTAL
Intervention: i‐FOBT
Number of subjects: 20623
Study 20560814 — intervention group
Group type: COMPARATOR
Intervention: g‐FOBT
Number of subjects: 20623
Study 17388709 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid initiation of quetiapine (200 mg on day 1, 400 mg on day 2, 600 mg on day 3, 800 mg on day 4)
Number of subjects: 40
Study 17388709 — intervention group
Group type: COMPARATOR
Intervention: Conventional initiation of quetiapine (50 mg on day 1, 100 mg on day 2, increased in 100 mg/day increments to reach 400 mg on day 5)
Number of subjects: 40
Study 17388709 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 16216030 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality Improvement (QI) program for CRC screening
Number of subjects: 32
Study 16216030 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 32
Study 12392586 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelin-1 (ET-1) infusion at 2.5 pmol min-1
Number of subjects: 8
Study 12392586 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelin-1 (ET-1) infusion at 10 pmol min-1
Number of subjects: 8
Study 10543321 — intervention group
Group type: EXPERIMENTAL
Intervention: midazolam-bupivacaine mixture (group M; n = 15)
Number of subjects: 30
Study 10543321 — intervention group
Group type: COMPARATOR
Intervention: bupivacaine alone (group B; n = 15)
Number of subjects: 30
Study 7750527 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose BCG (75 mg)
Number of subjects: 183
Study 7750527 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose BCG (150 mg)
Number of subjects: 183
Study 2125243 — intervention group
Group type: COMPARATOR
Intervention: Placebo for eight weeks
Number of subjects: 40
Study 2125243 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg of pravastatin daily for 24 weeks
Number of subjects: 40
Study 2125243 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg of pravastatin daily for 24 weeks
Number of subjects: 40
Study 2125243 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 gm of cholestyramine daily for 24 weeks
Number of subjects: 40
Study 2125243 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg of pravastatin plus 24 gm of cholestyramine daily for 24 weeks
Number of subjects: 40
Study 437308 — intervention group
Group type: EXPERIMENTAL
Intervention: Phyllocontin Continus tablets
Number of subjects: 24
Study 437308 — intervention group
Group type: COMPARATOR
Intervention: Alupent tablets
Number of subjects: 24
Study 437308 — intervention group
Group type: EXPERIMENTAL
Intervention: Phyllocontin tablets alone
Number of subjects: 24
Study 437308 — intervention group
Group type: COMPARATOR
Intervention: Ventolin tablets alone
Number of subjects: 24
Study 437308 — intervention group
Group type: EXPERIMENTAL
Intervention: Phyllocontin tablets with inhaled Ventolin
Number of subjects: 24
Study 437308 — intervention group
Group type: COMPARATOR
Intervention: Ventolin tablets with inhaled Ventolin
Number of subjects: 24
Study 31915173 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Early Warning Score (I-EWS)
Number of subjects: 150000
Study 31915173 — intervention group
Group type: COMPARATOR
Intervention: National Early Warning Score (NEWS)
Number of subjects: 150000
Study 30393978 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose breath tests (open twice and blinded once)
Number of subjects: 31
Study 30393978 — intervention group
Group type: COMPARATOR
Intervention: Water (blind neutral nocebo)
Number of subjects: 31
Study 30393978 — intervention group
Group type: COMPARATOR
Intervention: Cyclamate/saccharine sweetener (blind sweet nocebo)
Number of subjects: 31
Study 26233594 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 IA doses of PRP
Number of subjects: 162
Study 26233594 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 dose of PRP
Number of subjects: 162
Study 26233594 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 dose of HA
Number of subjects: 162
Study 26233594 — intervention group
Group type: COMPARATOR
Intervention: Saline injection (control)
Number of subjects: 162
Study 26233594 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 IA doses of PRP (early OA subgroup)
Number of subjects: 162
Study 26233594 — intervention group
Group type: EXPERIMENTAL
Intervention: Any treatment group (advanced OA subgroup)
Number of subjects: 162
Study 25920297 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of dexamethasone (8 mg) and metoclopramide (10 mg)
Number of subjects: 100
Study 25920297 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide (10 mg) with normal saline solution (1.6 ml)
Number of subjects: 100
Study 24013497 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose GH therapy (0.025 mg/kg/day)
Number of subjects: 16
Study 24013497 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose GH therapy (0.05 mg/kg/day)
Number of subjects: 16
Study 24013497 — intervention group
Group type: EXPERIMENTAL
Intervention: GH therapy (0.05 mg/kg/day for 12 months)
Number of subjects: 16
Study 20671716 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronized Intermittent Mandatory Ventilation (SIMV)
Number of subjects: 24
Study 20671716 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Frequency Oscillatory Ventilation (HFOV)
Number of subjects: 24
Study 19826305 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent stretching (2-3 days/week)
Number of subjects: 32
Study 19826305 — intervention group
Group type: COMPARATOR
Intervention: Standard stretching protocol (daily for 4 weeks, then discontinued)
Number of subjects: 32
Study 16952097 — intervention group
Group type: EXPERIMENTAL
Intervention: PPV with ILM removal
Number of subjects: 10
Study 16952097 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated fellow eyes)
Number of subjects: 10
Study 11996943 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (10-40 mg)
Number of subjects: 103
Study 11996943 — intervention group
Group type: COMPARATOR
Intervention: Bezafibrate (400 mg)
Number of subjects: 103
Study 10505027 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined modality treatment
Number of subjects: 194
Study 10505027 — intervention group
Group type: EXPERIMENTAL
Intervention: Enrolled in clinical trials
Number of subjects: 194
Study 10505027 — intervention group
Group type: COMPARATOR
Intervention: Treated outside of randomised studies
Number of subjects: 194
Study 10505027 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined modality regimens
Number of subjects: 194
Study 10505027 — intervention group
Group type: COMPARATOR
Intervention: Radiation or chemotherapy alone
Number of subjects: 194
Study 10505027 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients enrolled in clinical trials
Number of subjects: 194
Study 10505027 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall group of 225 patients
Number of subjects: 194
Study 7589657 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovulation induction with gonadotropins associated with timed vaginal intercourse (group A)
Number of subjects: 200
Study 7589657 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovulation induction with gonadotropins associated with IUI (group B)
Number of subjects: 200
Study 2371573 — intervention group
Group type: EXPERIMENTAL
Intervention: Diane contraceptive pill
Number of subjects: 59
Study 2371573 — intervention group
Group type: COMPARATOR
Intervention: Microgynon 50 contraceptive pill
Number of subjects: 59
Study 549212 — intervention group
Group type: EXPERIMENTAL
Intervention: S-adenosyl-L-methionine (SAMe)
Number of subjects: 0
Study 549212 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 0
Study 30626197 — intervention group
Group type: EXPERIMENTAL
Intervention: Sauti ya Vijana (The Voice of Youth) intervention, consisting of ten group sessions and two individual sessions led by trained group leaders.
Number of subjects: 0
Study 30626197 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 0
Study 27022625 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone administration in healthy individuals
Number of subjects: 0
Study 27022625 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone administration in chronic pain patients
Number of subjects: 0
Study 27022625 — intervention group
Group type: COMPARATOR
Intervention: Baseline condition in chronic pain patients
Number of subjects: 0
Study 26353815 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-cost simulation model
Number of subjects: 0
Study 26353815 — intervention group
Group type: EXPERIMENTAL
Intervention: High-cost simulation model
Number of subjects: 0
Study 26353815 — intervention group
Group type: COMPARATOR
Intervention: No simulation training
Number of subjects: 0
Study 23965480 — intervention group
Group type: EXPERIMENTAL
Intervention: True acupuncture
Number of subjects: 214
Study 23965480 — intervention group
Group type: COMPARATOR
Intervention: Nonpenetrating acupuncture
Number of subjects: 214
Study 21505219 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium and Vitamin D (1g calcium and 400 IU vitamin D daily)
Number of subjects: 36282
Study 21505219 — intervention group
Group type: COMPARATOR
Intervention: Calcium and Vitamin D
Number of subjects: 36282
Study 21505219 — intervention group
Group type: COMPARATOR
Intervention: Calcium or Calcium and Vitamin D
Number of subjects: 36282
Study 19011439 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 15 mg
Number of subjects: 313
Study 19011439 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 313
Study 16625452 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediocarpal arthrodesis (MA)
Number of subjects: 22
Study 16625452 — intervention group
Group type: COMPARATOR
Intervention: Total wrist arthrodesis (TA)
Number of subjects: 22
Study 13680082 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg doxepin (single i.v.)
Number of subjects: 10
Study 13680082 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg doxepin (subchronic p.o.)
Number of subjects: 10
Study 13680082 — intervention group
Group type: COMPARATOR
Intervention: Placebo (single i.v.)
Number of subjects: 10
Study 13680082 — intervention group
Group type: EXPERIMENTAL
Intervention: Both doxepin administrations
Number of subjects: 10
Study 10584984 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone 10 mg/day starting 1 month before ovulation induction for patients positive for ovarian autoantibodies (ov-ab).
Number of subjects: 80
Study 10584984 — intervention group
Group type: COMPARATOR
Intervention: Seronegative study group (no treatment).
Number of subjects: 80
Study 7787537 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral co-amoxiclav
Number of subjects: 541
Study 7787537 — intervention group
Group type: COMPARATOR
Intervention: Intravenous followed by oral co-amoxiclav
Number of subjects: 541
Study 7787537 — intervention group
Group type: COMPARATOR
Intervention: Intravenous followed by oral cephalosporins
Number of subjects: 541
Study 7787537 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral antibiotics
Number of subjects: 541
Study 7787537 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 541
Study 2081065 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behaviour therapy plus diazepam
Number of subjects: 101
Study 2081065 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behaviour therapy alone
Number of subjects: 101
Study 2081065 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behaviour therapy plus placebo
Number of subjects: 101
Study 2081065 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam alone
Number of subjects: 101
Study 2081065 — intervention group
Group type: COMPARATOR
Intervention: Placebo alone
Number of subjects: 101
Study 2081065 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behaviour therapy (either alone or in combination)
Number of subjects: 101
Study 2081065 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 101
Study 485782 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretraining using a cognitive-experiential approach
Number of subjects: 5
Study 485782 — intervention group
Group type: COMPARATOR
Intervention: Nonpretrained groups
Number of subjects: 5
Study 30937618 — intervention group
Group type: EXPERIMENTAL
Intervention: Full laparoscopic technique for minor resections
Number of subjects: 214
Study 30937618 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-assisted technique for minor resections
Number of subjects: 214
Study 30937618 — intervention group
Group type: EXPERIMENTAL
Intervention: Full laparoscopic technique for major resections
Number of subjects: 214
Study 30937618 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic technique for minor resections
Number of subjects: 214
Study 30937618 — intervention group
Group type: COMPARATOR
Intervention: Robotic technique for major resections
Number of subjects: 214
Study 30937618 — intervention group
Group type: COMPARATOR
Intervention: Hand-assisted technique for major resections
Number of subjects: 214
Study 30063297 — intervention group
Group type: EXPERIMENTAL
Intervention: Albiglutide 50 mg liquid formulation from an auto-injector (Regimen A)
Number of subjects: 59
Study 30063297 — intervention group
Group type: COMPARATOR
Intervention: Lyophilized placebo from a DCC pen-injector (Regimen A)
Number of subjects: 59
Study 30063297 — intervention group
Group type: COMPARATOR
Intervention: Placebo liquid from an auto-injector (Regimen B)
Number of subjects: 59
Study 30063297 — intervention group
Group type: EXPERIMENTAL
Intervention: Lyophilized albiglutide 50 mg from a DCC pen-injector (Regimen B)
Number of subjects: 59
Study 29284520 — intervention group
Group type: EXPERIMENTAL
Intervention: TangBi Formula plus mecobalamin
Number of subjects: 188
Study 29284520 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus mecobalamin
Number of subjects: 188
Study 26725253 — intervention group
Group type: EXPERIMENTAL
Intervention: Definitely echolucent plaques (> 25% soft plaque)
Number of subjects: 814
Study 26725253 — intervention group
Group type: COMPARATOR
Intervention: Definitely nonecholucent plaques (< 25% soft plaque)
Number of subjects: 814
Study 26725253 — intervention group
Group type: EXPERIMENTAL
Intervention: Plaque echolucency
Number of subjects: 814
Study 25379844 — intervention group
Group type: EXPERIMENTAL
Intervention: Circular plastic wound edge protectors (CWEPs)
Number of subjects: 608
Study 25379844 — intervention group
Group type: COMPARATOR
Intervention: Standard surgical towels (control)
Number of subjects: 608
Study 23248412 — intervention group
Group type: EXPERIMENTAL
Intervention: Papaya dressing
Number of subjects: 64
Study 23248412 — intervention group
Group type: COMPARATOR
Intervention: Hydrogen peroxide dressing
Number of subjects: 64
Study 19254119 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole 500 mg and Amoxicillin 375 mg, three times a day for 7 days
Number of subjects: 51
Study 19254119 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 17223217 — intervention group
Group type: EXPERIMENTAL
Intervention: vildagliptin 50 mg qd
Number of subjects: 354
Study 17223217 — intervention group
Group type: EXPERIMENTAL
Intervention: vildagliptin 50 mg bid
Number of subjects: 354
Study 17223217 — intervention group
Group type: EXPERIMENTAL
Intervention: vildagliptin 100 mg qd
Number of subjects: 354
Study 17223217 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 354
Study 15840675 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet
Number of subjects: 14
Study 12678168 — intervention group
Group type: EXPERIMENTAL
Intervention: Zuclopenthixol acetate (ZPTA) 50-100 mg
Number of subjects: 70
Study 12678168 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (HAL) 5-10 mg
Number of subjects: 70
Study 9619545 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine needle aspiration (FNA)
Number of subjects: 102
Study 9619545 — intervention group
Group type: COMPARATOR
Intervention: Open excisional biopsy
Number of subjects: 102
Study 7622272 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor 250 mg at bedtime for 12 months
Number of subjects: 120
Study 7622272 — intervention group
Group type: EXPERIMENTAL
Intervention: Macrocrystalline nitrofurantoin 50 mg at bedtime for 12 months
Number of subjects: 120
Study 29233615 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher overall HEI‐2010 score (healthier diet)
Number of subjects: 44
Study 29233615 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher HEI‐2010 score in women with prior chemotherapy
Number of subjects: 44
Study 29233615 — intervention group
Group type: EXPERIMENTAL
Intervention: HEI‐2010 score
Number of subjects: 44
Study 27595722 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodentine
Number of subjects: 90
Study 27595722 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral Trioxide Aggregate (MTA)
Number of subjects: 90
Study 26441146 — intervention group
Group type: EXPERIMENTAL
Intervention: Heroin administration
Number of subjects: 49
Study 26441146 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 49
Study 23104147 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous femoral nerve block alone (group F)
Number of subjects: 89
Study 23104147 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-injection sciatic nerve block combined with continuous femoral nerve block (group Fs)
Number of subjects: 89
Study 23104147 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous sciatic nerve block combined with continuous femoral nerve block (group FCS)
Number of subjects: 89
Study 21357381 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype-environment interactions tested using genome-wide data
Number of subjects: 1191
Study 21357381 — intervention group
Group type: EXPERIMENTAL
Intervention: Previously reported susceptibility loci
Number of subjects: 1191
Study 19791831 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 5% medicated plaster
Number of subjects: 0
Study 16890834 — intervention group
Group type: EXPERIMENTAL
Intervention: fosamprenavir-ritonavir 700 mg/100 mg twice daily
Number of subjects: 878
Study 16890834 — intervention group
Group type: COMPARATOR
Intervention: lopinavir-ritonavir 400 mg/100 mg twice daily
Number of subjects: 878
Study 16890834 — intervention group
Group type: EXPERIMENTAL
Intervention: fosamprenavir-ritonavir
Number of subjects: 878
Study 16890834 — intervention group
Group type: COMPARATOR
Intervention: lopinavir-ritonavir
Number of subjects: 878
Study 15253741 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron administration (40 mg of saccharated ferric oxide after every dialysis session for four weeks)
Number of subjects: 22
Study 15253741 — intervention group
Group type: COMPARATOR
Intervention: Control group (vehicle treatment)
Number of subjects: 22
Study 11509476 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium depletion (acute)
Number of subjects: 158
Study 11509476 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium depletion (chronic)
Number of subjects: 158
Study 11509476 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (2-hour)
Number of subjects: 158
Study 11509476 — intervention group
Group type: COMPARATOR
Intervention: Controlled sodium intake
Number of subjects: 158
Study 11509476 — intervention group
Group type: COMPARATOR
Intervention: Salt-sensitive group (baseline)
Number of subjects: 158